Physician profile
Halimeh Farhat
NPI 1750094223
$2,820.39
in general payments reported to CMS, 2019-2025
23 companies · $2,411 in 2025
The $2,411 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $275 · 2024: $20.15 · 2025: $2,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.47 |
| Education | $279.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.68 | 2025 | |
| Sun Pharmaceutical Industries INC. | $312.65 | 2025 | |
| Janssen Biotech, INC. | $299.91 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $189.64 | 2025 | |
| Genzyme Corporation | $181.27 | 2025 | |
| Ucb, INC. | $179.40 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $172.68 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $138.79 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $138.56 | 2023 | Krystexxa |
| Lilly USA, LLC | $134.98 | 2025 | Ebglyss, Taltz |
| Astrazeneca Pharmaceuticals LP | $118.06 | 2023 | Farxiga |
| Arcutis Biotherapeutics, INC. | $103.73 | 2025 | Zoryve |
| Organon LLC | $80.78 | 2025 | |
| Lnhc, INC | $41.72 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $41.40 | 2025 | Spevigo, Anzupgo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.39 | 2025 | Cabtreo |
| Incyte Corporation | $27.78 | 2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $27.08 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.69 | 2025 | Spevigo |
| Stryker Corporation | $20.15 | 2024 | Triathlon, Mako, Insignia |
| Pinnacle, INC | $18.76 | 2023 | |
| Amgen INC. | $17.16 | 2025 | Otezla |
| Mayne Pharma Commercial LLC | $15.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halimeh Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.